Institution · IQVIA (United States)
Most cited papers from IQVIA (United States)
What are the most cited papers from IQVIA (United States)?
The most cited paper from IQVIA (United States) is "Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach" (Elizabeth R. DeLong, David M. DeLong, Daniel L. Clarke‐Pearson, 1988), with 23,031 citations. Next come "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia" (5,930) and "Edoxaban versus Warfarin in Patients with Atrial Fibrillation" (5,195).
Showing 50 of 60 papers. Every paper with more than 303 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach Elizabeth R. DeLong, David M. DeLong, Daniel L. Clarke‐Pearson · Biometrics | Sep 1988 | 23,031 |
| 2 | Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey Alan Lieberman, T. Scott Stroup, Joseph P. McEvoy et al. · New England Journal of Medicine | 19 Sep 2005 | 5,930 |
| 3 | Edoxaban versus Warfarin in Patients with Atrial Fibrillation Robert Patrick Giugliano et al. · New England Journal of Medicine | 19 Nov 2013 | 5,195 |
| 4 | Burden of Gastrointestinal Disease in the United States: 2012 Update Anne F. Peery, Evan S. Dellon, Jennifer Leigh Lund et al. · Gastroenterology | 8 Aug 2012 | 2,038 |
| 5 | Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease Adeera Levin, George L. Bakris, Mark E. Molitch et al. · Kidney International | 8 Nov 2006 | 1,522 |
| 6 | Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis Milisa Blagojevic, Clare Jinks, Amanda Jeffery et al. · Osteoarthritis and Cartilage | 3 Sep 2009 | 1,421 |
| 7 | Seed Germination and Vigor Loïc Rajjou, Manuel X. Duval, Karine Gallardo et al. · Annual Review of Plant Biology | 3 May 2012 | 1,284 |
| 8 | Validity and Reliability of the Observer??s DORIS A. CHERNIK, Dennis B. Gillings, HARRIET LAINE et al. · Journal of Clinical Psychopharmacology | Aug 1990 | 1,262 |
| 9 | Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease Lon S. S. Schneider, Pierre N. Tariot, Karen Dagerman et al. · New England Journal of Medicine | 11 Oct 2006 | 1,202 |
| 10 | An Extensive New Literature Concerning Low-Dose Effects of Bisphenol A Shows the Need for a New Risk Assessment Frederick S. vom Saal, Claude L. Hughes · Environmental Health Perspectives | 12 Apr 2005 | 1,175 |
| 11 | Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Joseph P. McEvoy, Jonathan M. Meyer, DONALD C. GOFF et al. · Schizophrenia Research | 31 Aug 2005 | 1,143 |
| 12 | Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs Fred E. Silverstein, David Y. Graham, John R. Senior et al. · Annals of Internal Medicine | 15 Aug 1995 | 1,064 |
| 13 | Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Mark J. Atkinson, Anusha Sinha, Steven Hass et al. · Health and Quality of Life Outcomes | 2004 | 1,009 |
| 14 | Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho et al. · New England Journal of Medicine | 28 Aug 2013 | 981 |
| 15 | The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States Michael D. Kappelman, Sheryl L. Rifas‐Shiman, KEN P. KLEINMAN et al. · Clinical Gastroenterology and Hepatology | Oct 2007 | 937 |
| 16 | Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis Tasha E. Fingerlin et al. · Nature Genetics | 14 Apr 2013 | 842 |
| 17 | A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women Pirow J. Bekker, Donna L. Holloway, Amy S Rasmussen et al. · Journal of Bone and Mineral Research | Jul 2004 | 773 |
| 18 | The burden of skin diseases: 2004 David R. Bickers, Henry W. Lim, David J Margolis et al. · Journal of the American Academy of Dermatology | 13 Aug 2006 | 743 |
| 19 | MolTrans: Molecular Interaction Transformer for drug–target interaction prediction Kexin Huang, Cao Xiao, Lucas M. Glass et al. · Bioinformatics | 7 Oct 2020 | 676 |
| 20 | Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Evan A. Stein, Scott J. Mellis, George D. Yancopoulos et al. · New England Journal of Medicine | 22 Mar 2012 | 673 |
| 21 | Epidemiology of Ankle Sprains and Chronic Ankle Instability Mackenzie M. Herzog, Zachary Y. Kerr, Stephen W. Marshall et al. · Journal of Athletic Training | 28 May 2019 | 658 |
| 22 | The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment Melissa Anne Haendel et al. · Journal of the American Medical Informatics Association | 14 Aug 2020 | 604 |
| 23 | Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Sally E. Wenzel, Darren Wilbraham, Rick W. Fuller et al. · The Lancet | Oct 2007 | 588 |
| 24 | Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Kevin J. Fitzgerald, Maria D. Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet | 3 Oct 2013 | 580 |
| 25 | Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures Caroline Barbara Terwee, John Devin Peipert, Robert S. Chapman et al. · Quality of Life Research | 10 Jul 2021 | 571 |
| 26 | Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina BERNARD R. CHAITMAN, Sandra L. Skettino, John O. Parker et al. · Journal of the American College of Cardiology | Apr 2004 | 569 |
| 27 | US Outpatient Antibiotic Prescribing Variation According to Geography, Patient Population, and Provider Specialty in 2011 Lauri A. Hicks, Monina G. Bartoces, Rebecca M. Roberts et al. · Clinical Infectious Diseases | 5 Mar 2015 | 565 |
| 28 | Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline Henry A. Nasrallah, Jonathan M. Meyer, DONALD C. GOFF et al. · Schizophrenia Research | 2 Aug 2006 | 560 |
| 29 | Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium Philip T. Sager, Gary A. Gintant, J. Rick Turner et al. · American Heart Journal | 2 Dec 2013 | 554 |
| 30 | Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers Henry Mark Dunnenberger, Kristine R. Crews, James M. Hoffman et al. · The Annual Review of Pharmacology and Toxicology | 8 Oct 2014 | 521 |
| 31 | Gender differences in chronic major and double depression Susan G. Kornstein, Alan F. Schatzberg, Michael E. Thase et al. · Journal of Affective Disorders | Oct 2000 | 508 |
| 32 | DeepPurpose: a deep learning library for drug–target interaction prediction Kexin Huang, Tianfan Fu, Lucas M. Glass et al. · Bioinformatics | 20 Nov 2020 | 507 |
| 33 | Avosentan for Overt Diabetic Nephropathy Johannes F.E. Mann, Damian Green, Kenneth Jamerson et al. · Journal of the American Society of Nephrology | 18 Feb 2010 | 493 |
| 34 | The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women Pirow J. Bekker, Donna L. Holloway, Arline M. Nakanishi et al. · Journal of Bone and Mineral Research | Feb 2001 | 493 |
| 35 | Basal Insulin Therapy in Type 2 Diabetes Julio Rosenstock, Sherwyn Leon Schwartz, Charles M. Clark et al. · Diabetes Care | Apr 2001 | 482 |
| 36 | Race/Ethnic Issues in Obesity and Obesity-Related Comorbidities Nicole Cossrow, Bonita E. Falkner · The Journal of Clinical Endocrinology & Metabolism | Jun 2004 | 475 |
| 37 | Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial Richard S.E. Keefe, Robert M. Bilder, Philip D. Harvey et al. · Neuropsychopharmacology | 19 Apr 2006 | 473 |
| 38 | Opportunities and challenges of deep learning methods for electrocardiogram data: A systematic review Shenda Hong, Yuxi Zhou, Junyuan Shang et al. · Computers in Biology and Medicine | 7 Jun 2020 | 471 |
| 39 | Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition et al. · Nature Reviews Drug Discovery | 28 Aug 2019 | 415 |
| 40 | Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial Christian Thomas Ruff, Robert Patrick Giugliano, Eugene Braunwald et al. · The Lancet | 10 Mar 2015 | 407 |
| 41 | Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study Augustus John Rush, Harold A. Sackeïm, Lauren B. Marangell et al. · Biological Psychiatry | Sep 2005 | 402 |
| 42 | Unexplored therapeutic opportunities in the human genome Tudor Ionel Oprea et al. · Nature Reviews Drug Discovery | 23 Feb 2018 | 398 |
| 43 | Patient‐reported reasons for discontinuing overactive bladder medication Joshua S. Benner, Michael B. Nichol, Eric Scott Rovner et al. · British Journal of Urology | 12 Nov 2009 | 395 |
| 44 | Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis Marc A. Suchard, Martijn J. Schuemie, Harlan M. Krumholz et al. · The Lancet | 24 Oct 2019 | 394 |
| 45 | Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States Rohini Khorana Hernandez, Sally W. Wade, Adam Reich et al. · BMC Cancer | 6 Jan 2018 | 386 |
| 46 | Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component Duncan Richards, Louise M. Cookson, Aliénor Berges et al. · New England Journal of Medicine | 15 Jul 2015 | 382 |
| 47 | A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression Mark S. George, Augustus John Rush, Lauren B. Marangell et al. · Biological Psychiatry | Sep 2005 | 373 |
| 48 | Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy John Pasi et al. · New England Journal of Medicine | 10 Jul 2017 | 365 |
| 49 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Extended-Release Carbamazepine Capsules as Monotherapy for Bipolar Disorder Patients With Manic or Mixed Episodes Richard H. Weisler, Amir H Kalali, Terence A. Ketter et al. · The Journal of Clinical Psychiatry | 15 Apr 2004 | 354 |
| 50 | Characterizing treatment pathways at scale using the OHDSI network George M. Hripcsak, Patrick B. Ryan, Jon D Duke et al. · Proceedings of the National Academy of Sciences | 6 Jun 2016 | 351 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.